Cargando…
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this treatment induces complete remissions in the majority of patients, many face a relapse (adaptive resistance) or have ref...
Autores principales: | van Gils, Noortje, Denkers, Fedor, Smit, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126717/ https://www.ncbi.nlm.nih.gov/pubmed/34012921 http://dx.doi.org/10.3389/fonc.2021.659253 |
Ejemplares similares
-
The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
por: van Gils, Noortje, et al.
Publicado: (2021) -
Leukemic stem cells and therapy resistance in acute myeloid leukemia
por: Stelmach, Patrick, et al.
Publicado: (2023) -
Extramedullary Acute Myeloid Leukemia: Leukemic Pleural Effusion, Case Report and Review of the Literature
por: Pemmaraju, Naveen, et al.
Publicado: (2014) -
Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells
por: Peng, Meixi, et al.
Publicado: (2022) -
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia
por: Galimberti, Sara, et al.
Publicado: (2018)